Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger Welcome to LiverHealthGroup.com Built to Help You Fight Forward Your Story Isn’t Over — It’s Getting Stronger

This is a centralized dashboard for my personal medical information. It is designed for streamlined access to key health metrics without the requirement of logging into third-party applications, such as the Kaiser portal. A key objective of this page is to facilitate the harvesting and in-depth analysis of this data by artificial intelligence systems to generate advanced health insights. This approach is intended to deepen my understanding of my health conditions and help identify effective management strategies in a timely manner by leveraging the latest available technologies.

My Blood Test Results

CBC (Complete Blood Count) with Differential
Collected on Jun 11, 2026 at 6:08 PM

Overall AI Assessment

✓Stable

Risk: Moderate

Trend: Decreasing
AI Confidence
96%
High Confidence

Today’s Wins

✓RBC Normal✓Hemoglobin Normal✓Hematocrit Normal✓MCV Normal✓MCH Normal✓MCHC Normal✓RDV, CV Normal✓RDW, SD Normal
8 / 10 markers in normal range

Watch Closely

  • WBC (Leukopenia)
  • Platelet Count

Continue monitoring these markers for any changes.

Current Concern

68%Moderate
Based on entered abnormal results

AI Health Summary

Your WBC is 1.88 x10(9)/L, below the entered reference range. 8 entered CBC markers are within the entered reference ranges. This suggests the abnormality should be monitored as part of the full CBC pattern.

WBC Trend(2 Results)
2.38Mar 3, 20261.88Jun 11, 2026
Interpretation: Your WBC has been consistently outside the normal range and should be monitored with follow-up testing.
-21.0%from previous
Slow decline detected.

Considering Your Health Profile

  • Liver Cirrhosis
  • Portal Hypertension
  • Splenomegaly
  • Portal Vein Thrombosis

Current medications:
Eliquis, Carvedilol, Atorvastatin

The most likely explanation for your low WBC may involve hypersplenism related to splenomegaly and portal hypertension.

Confidence:★ ★ ★ ★★(High)

AI Weekly Summary

Most entered CBC markers remain stable. Abnormal values should be reviewed as part of the full CBC pattern and compared with prior testing rather than interpreted alone.

8Normal2Low0High

No new patterns suggesting worsening anemia are present.

Continue following your physician’s recommendations and monitor future CBC results for trends rather than focusing on a single value.

Personalized Recommendations

  • Discuss persistent abnormal CBC values and possible causes with your healthcare team.
  • Request ANC when clinically appropriate.
  • Repeat CBC according to your clinician’s plan.
  • Report fever, chills, unusual bleeding, or infection symptoms promptly.

What is Leukopenia?

Low white blood cell count. It can increase risk of infections because your body has fewer cells to fight bacteria, viruses, and other germs.

AI Trend Estimate (WBC)

If the recent trend continues, the next result could remain close to the current value.

1.88 – 2.11 x10(9)/L
Expected next range
Confidence78%
TestResultReference rangeStatusChangeAI Insights
WBCWhite Blood Cells
1.88x10(9)/LLow
4 - 10.5 x10(9)/L
410.5
LowBelow range
↓ -0.5-21.0%
vs 2.38
CRITICAL RESULTSResults called to and verified by your healthcare team.
RBCRed Blood Cells
4.8x10(12)/LNormal
4 - 5.5 x10(12)/L
45.5
NormalIn range
↑ +0.02+0.4%
vs 4.78
HemoglobinHemoglobin in Blood
13.5gm/dLNormal
13 - 17 gm/dL
1317
NormalIn range
↓ -0.1-0.7%
vs 13.6
HematocritPercentage of RBCs
40.9%Normal
37 - 50 %
3750
NormalIn range
↓ -0.4-1.0%
vs 41.3
MCVMean Corpuscular Volume
85.2fLNormal
80 - 100 fL
80100
NormalIn range
↓ -1.2-1.4%
vs 86.4
MCHMean Corpuscular Hemoglobin
28.1pgNormal
28 - 35 pg
2835
NormalIn range
↓ -0.4-1.4%
vs 28.5
MCHCMean Corpuscular Hemoglobin Concentration
33gm/dLNormal
31 - 36.5 gm/dL
3136.5
NormalIn range
↑ +0.1+0.3%
vs 32.9
RDV, CVRed Cell Distribution Width - Coefficient of Variation
13.9%Normal
11 - 14.5 %
1114.5
NormalIn range
↑ +0.1+0.7%
vs 13.8
RDW, SDRed Cell Distribution Width — Standard Deviation
43.5fLNormal
36 - 50 fL
3650
NormalIn range
↓ -0.1-0.2%
vs 43.6
Platelet CountThrombocytes
30x10(9)/LLow
140 - 375 x10(9)/L
140375
LowBelow range
↓ -1-3.2%
vs 31
CRITICAL RESULTSResults called to and verified by your healthcare team.

My Liver Index Panel

Latest collection date: 2026-06-21

Analysis ready
ScoreCalculated

MELD 3.0 Score

Uses bilirubin, INR, creatinine, sodium, albumin, sex and dialysis status.

10
↓ Improved 1 point since last test
Previous
11
Current
10
↓-1
MELD Risk Range
6152540
Low < 15Moderate 15–25High > 25

AI Explanation: The MELD score estimates the severity of chronic liver disease and supports transplant-priority assessment. A lower score generally indicates lower short-term risk.

Sodium (Na)
Normal
139mmol/L

Reference: 136–145 mmol/L

Previous
140mmol/L
Current
139mmol/L
↓-1
136145
AI explanation

Sodium helps regulate fluid balance, nerves and muscles. Liver disease can affect sodium when the body retains excess fluid.

Potassium (K)
Normal
4.2mmol/L

Reference: 3.5–5.1 mmol/L

Previous
3.99mmol/L
Current
4.2mmol/L
↑+0.21
3.55.1
AI explanation

Potassium supports heart rhythm, nerves and muscles. Medicines, kidney function and fluid shifts can change it.

BUN
High
21mg/dL

Reference: 6–20 mg/dL

Previous
20mg/dL
Current
21mg/dL
↑+1
620
AI explanation

BUN reflects nitrogen waste from protein metabolism. Hydration, kidney function, bleeding and protein intake can influence it.

Creatinine
Normal
0.82mg/dL

Reference: 0.67–1.17 mg/dL

Previous
0.87mg/dL
Current
0.82mg/dL
↓-0.05
0.671.17
AI explanation

Creatinine is used to estimate kidney function and is an important part of the MELD calculation.

Total Bilirubin
Normal
1.2mg/dL

Reference: ≤1.2 mg/dL

Previous
1.7mg/dL
Current
1.2mg/dL
↓-0.5
01.2
AI explanation

Bilirubin is a pigment processed by the liver. Higher levels can suggest reduced processing or impaired bile flow.

Total Protein
Normal
7.2g/dL

Reference: 6.4–8.3 g/dL

Previous
7.1g/dL
Current
7.2g/dL
↑+0.1
6.48.3
AI explanation

Total protein measures albumin plus other blood proteins and helps show nutrition, liver production and immune-protein balance.

Albumin
Normal
4.3g/dL

Reference: 3.5–5.2 g/dL

Previous
4.6g/dL
Current
4.3g/dL
↓-0.3
3.55.2
AI explanation

Albumin is a major protein made by the liver. It helps keep fluid in blood vessels and reflects liver synthetic function over time.

AST (GOT)
Normal
36U/L

Reference: ≤50 U/L

Previous
35U/L
Current
36U/L
↑+1
050
AI explanation

AST is an enzyme found in liver and muscle cells. A rise can reflect cell injury but is not specific to the liver alone.

ALT (SGPT)
Normal
47U/L

Reference: 10–50 U/L

Previous
47.7U/L
Current
47U/L
↓-0.7
1050
AI explanation

ALT is an enzyme more closely associated with liver cells. Higher values can indicate active liver-cell injury.

Alkaline Phosphatase
Low
38U/L

Reference: 40–129 U/L

Previous
33U/L
Current
38U/L
↑+5
40129
AI explanation

Alkaline phosphatase is linked mainly to bile ducts and bone. Abnormal values are interpreted with other liver tests.

INR
High
1.4

Reference: 0.9–1.2

Previous
1.3
Current
1.4
↑+0.1
0.91.2
AI explanation

INR measures how long blood takes to clot. It reflects clotting-factor production but anticoagulants can strongly affect the result.

✦

AI Health Summary

Automated pattern analysis of your two latest test sets

Overall Status

MELD 3.0 decreased from 11 to 10.

3 displayed measurement(s) are outside range.

Key Findings

  • BUN is high (21).
  • Alkaline Phosphatase is low (38).
  • INR is high (1.4).

Changes Since Prior Test

  • Total Bilirubin moved toward its reference range; Alkaline Phosphatase moved toward its reference range.
  • BUN moved farther from its reference range; INR moved farther from its reference range.
Automated analysis is informational and is not medical advice. Clinical interpretation and any official transplant score must be confirmed by your healthcare team.

Blood Pressure & Vital Signs

Track blood pressure, oxygen saturation and heart rate over time

Last 30 days
Average Blood Pressure
121 / 66 mmHg
Elevated

Normal reference: <120/80 mmHg

Average SpO₂
98%
Excellent

Typical reference: 95%–100%

Average Heart Rate
61 bpm
Normal

Medication-aware threshold: 50 bpm

Measurements
11
Recorded

Displayed dataset

Month
July 2026
Current

Latest reading month

Date
Blood Pressure
SpO₂
Heart Rate
Month
Notes
Jul 28, 202618:48
128 / 66mmHg
ElevatedReference: <120/80
96%
Excellent
59bpm
NormalCarvedilol noted
July2026
Carvedilol taken at 6:50 am
Jul 26, 202609:26
114 / 58mmHg
OptimalReference: <120/80
97%
Excellent
52bpm
NormalCarvedilol noted
July2026
2.5 hrs post-waking | 1.5 hrs post-dose (Carvedilol Peak)
Jul 25, 202607:25
130 / 71mmHg
HighReference: <120/80
98%
Excellent
52bpm
NormalCarvedilol noted
July2026
After resting 5 minutes - Morning reading
Aug 31, 202514:11
121 / 66mmHg
ElevatedReference: <120/80
99%
Excellent
65bpm
NormalCarvedilol noted
August2025
After resting 5 minutes
Aug 30, 202508:45
117 / 67mmHg
OptimalReference: <120/80
100%
Excellent
64bpm
NormalCarvedilol noted
August2025
Morning reading
Aug 29, 202507:50
125 / 72mmHg
ElevatedReference: <120/80
98%
Excellent
68bpm
NormalMedication timing not marked
August2025
Slightly stressed
Aug 28, 202520:30
119 / 65mmHg
OptimalReference: <120/80
98%
Excellent
63bpm
NormalCarvedilol noted
August2025
Evening reading
Aug 27, 202507:30
118 / 64mmHg
OptimalReference: <120/80
97%
Excellent
62bpm
NormalCarvedilol noted
August2025
After workout recovery
Aug 26, 202508:10
116 / 63mmHg
OptimalReference: <120/80
99%
Excellent
60bpm
NormalCarvedilol noted
August2025
Well rested
Aug 25, 202519:15
122 / 68mmHg
ElevatedReference: <120/80
98%
Excellent
66bpm
NormalCarvedilol noted
August2025
Evening reading
Aug 24, 202509:05
120 / 67mmHg
ElevatedReference: <120/80
99%
Excellent
64bpm
NormalCarvedilol noted
August2025
Weekend morning

Medication-Aware Analysis

AI-style trend interpretation

Your average blood pressure is 121/66 mmHg, average heart rate is 61 bpm, and average SpO₂ is 98%. Blood pressure is elevated and the heart-rate trend is trending lower. 91% of the displayed readings were marked as taken after Carvedilol. The medication-aware review found 0 reading(s) below your configured low-value thresholds.

BP StabilityTrending higher
Average BP121 / 66
Heart Rate TrendTrending lower
SpO₂ StatusExcellent
Medication ImpactCarvedilol
Carvedilol is a beta-blocker that can lower blood pressure and heart rate. The analysis compares readings with medication timing and flags unusually low values or meaningful changes from your personal average.

AI-style insights are informational and are not medical advice. Medication effects vary by person. Contact your medical team for symptoms, very low readings, faintness, chest pain, shortness of breath, or sudden changes.

Trend Overview

Latest 10 measurements with averages, ranges and medication context
Average BP121 / 66mmHg
Average Heart Rate61bpm
Average SpO₂98%oxygen saturation
Measurements10shown in charts

Blood Pressure

Latest 128 / 66 mmHg

SystolicDiastolic

Heart Rate

Latest 59 bpm

Medication aware

SpO₂

Latest 96%

95% threshold
⌂ Home›Medical Panels›Lipid Panel
♡+

LIPID PANEL

Track your cholesterol and lipid levels over time to support cardiovascular health.

♡
TOTAL CHOLESTEROL
111 mg/dL
Normal: < 239 mg/dL
Normal
LDL
LDL (BAD)
51 mg/dL
Optimal: < 100 mg/dL
Optimal
HDL
HDL (GOOD)
51 mg/dL
Optimal: ≥ 40 mg/dL
Optimal
◔
TRIGLYCERIDES
47 mg/dL
Normal: < 150 mg/dL
Normal
AI
AI CARDIOVASCULAR SCORE
Excellent
Overall lipid control is excellent.
Low Risk
FEATURED LIPID INSIGHT

CALCULATED REMNANT CHOLESTEROL

9 mg/dLExcellent / Very Low
111 Total Cholesterol − 51 HDL − 51 LDL = 9 mg/dL

Remnant cholesterol estimates cholesterol carried in triglyceride-rich remnant particles. Your calculated result is low and complements your favorable LDL and triglyceride results.

AUTOMATED FROM YOUR LATEST PANEL

ADVANCED LIPID SIGNALS

These calculated values update automatically whenever the newest lipid-panel row changes.

Latest: 2026-06-12
Favorable

NON-HDL CHOLESTEROL

60 mg/dL
111 − 51 = 60

Captures cholesterol carried by LDL and other potentially atherogenic particles.

Favorable

TG / HDL RATIO

0.92 ratio
47 ÷ 51 = 0.92

A compact view of triglycerides relative to protective HDL cholesterol.

Favorable

TOTAL / HDL RATIO

2.18 ratio
111 ÷ 51 = 2.18

Shows total cholesterol in relation to HDL; lower values are generally more favorable.

Favorable

LDL / HDL RATIO

1.00 ratio
51 ÷ 51 = 1.00

Compares LDL with HDL and provides another view of the balance between the two.

Calculated values add useful context but do not replace your clinician’s interpretation or a formal cardiovascular-risk assessment.

AUTOMATED SUMMARY

LIPID PROFILE SUMMARY

A transparent, automatically calculated snapshot of the values entered in this widget.

100/100Excellent
LDL51 mg/dL
HDL51 mg/dL
Triglycerides47 mg/dL
Non-HDL60 mg/dL
Remnant9 mg/dL
Ratios2.18 TC/HDL

This is an informational dashboard score, not a validated cardiovascular-risk calculator or medical diagnosis.

▣LIPID PANEL HISTORY
PatientDateTotal CholLDLHDLTriglyceridesAI StatusMonth
SashaKaiser Permanente 2026-06-1207:07 111 mg/dLNormal: < 239 51 mg/dLOptimal: < 100 51 mg/dLOptimal: ≥ 40 47 mg/dLNormal: < 150 Excellent June
SashaKaiser Permanente 2025-03-2910:17 94 mg/dLNormal: < 239 33 mg/dLOptimal: < 100 50 mg/dLOptimal: ≥ 40 57 mg/dLNormal: < 150 Excellent March
Sasha Kaiser Permanente 2024-02-2912:11 128 mg/dLNormal: < 239 70 mg/dLOptimal: < 100 38 mg/dLOptimal: ≥ 40 101 mg/dLNormal: < 150 HDL Low February
Sasha Kaiser Permanente 2023-06-0110:58 85 mg/dLNormal: < 239 31 mg/dLOptimal: < 100 41 mg/dLOptimal: ≥ 40 64 mg/dLNormal: < 150 Excellent June
SashaKaiser Permanente 2023-02-2711:40 69 mg/dLNormal: < 239 25 mg/dLOptimal: < 100 24 mg/dLOptimal: ≥ 40 102 mg/dLNormal: < 150 HDL Very Low February
AI

AI CARDIOVASCULAR SUMMARY

  • LDL decreased and remains in the optimal range.
  • HDL improved from earlier results.
  • Triglycerides remain well controlled.
  • Total cholesterol remains in a healthy range.

AI summaries are informational and are not a substitute for professional medical advice.

✓This table summarizes your historical lipid measurements and trends. Prepared from Kaiser Permanente laboratory results.

CORONARY ARTERY HEALTH

Based on Cardiac Catheterization (Angiogram)
Last UpdatedJanuary 2024

Left Main (LM)

No obstructive disease
Normal

LAD (Left Anterior Descending)

70% proximal narrowing
Mid vessel occluded
Critical

LCX (Left Circumflex)

70% mid vessel stenosis
70%

Diagonal Branch

50% proximal stenosis
50%

RCA (Right Coronary Artery)

Dominant vessel
Mild disease
Mild

RPDA

60% mid stenosis
Mild diffuse disease
60%
Left Main (LM) LAD LCX Diagonal RCA RPDA Collateral circulation from RCA to LAD
Hover or click an artery to see details

HEART PRESSURE (LVEDP)

27 mmHg
Normal: 5–12 mmHg
27
012202840
LowNormalElevatedHigh

✦ AI CARDIOVASCULAR SUMMARY

This angiogram shows multivessel coronary artery disease. The LAD has severe proximal narrowing and a mid-vessel occlusion, with partial collateral support from the RCA. The report states that LIMA–LAD bypass could provide the best long-term benefit, but surgery was not considered safe at that time because of multi-organ failure.

This AI analysis is based on the data you have provided and is for informational purposes only. It is not a substitute for professional medical advice.

Iron Status Panel

Iron metabolism, storage and transport

Last update Jul 23, 2026
All results in normal range

Iron

Serum Iron
75 mcg/dL
✓Normal

Amount of circulating iron available in your bloodstream.

Range: 61 - 157 mcg/dL

TIBC

Total Iron Binding Capacity
298.4 mcg/dL
✓Normal

Measures how much iron your blood is capable of carrying.

Range: 228.0 - 428.0 mcg/dL

% Saturation

Transferrin Saturation
25 %
✓Normal

Percentage of transferrin currently carrying iron.

Range: 20 - 50 %

Ferritin

Iron Stores
116 ng/mL
✓Healthy Stores

Reflects your body’s stored iron reserves.

Range: 35 - 463 ng/mL
⚖

Iron Balance Overview

Overall assessment of your iron status

Iron Availability

PoorBalancedExcellent
Current Status Balanced

All four iron markers are within their configured reference ranges.

Storage (Ferritin)Healthy
18.9%
Transport (TIBC)Normal
35.2%
Utilization (Saturation)Efficient
16.7%
🤖

AI Iron Analysis

  • ✓Your current iron studies are well balanced.
  • ✓Serum iron is within the normal range, indicating adequate circulating iron available for red blood cell production.
  • ✓Ferritin is 116 ng/mL, showing healthy iron stores. Compared with your previous ferritin values, this suggests your iron deficiency has been successfully corrected and remains stable.
  • ✓TIBC remains comfortably within the reference interval, meaning your body is not showing the pattern typically seen with iron deficiency.
  • ✓Transferrin saturation is 25%, demonstrating that approximately one-quarter of available transport proteins are carrying iron.
  • ✓Taken together, these results do not suggest iron deficiency or iron overload.
♡ Overall: Your iron status is healthy and stable. Continue routine monitoring as recommended by your doctor.
↗

Progress Since Previous Tests

Ferritin trend over time (ng/mL)

18 May 17, 2025 Iron Deficiency
56 Jun 10, 2025 Improving
87 Aug 02, 2025 Stable
116 Jul 23, 2026 Current
↗
Recovery Score92%

Ferritin has increased from iron-deficient levels into the healthy range. Iron stores have improved significantly and remain stable.

🤖

AI Progress Summary

  • ✓Ferritin has increased from iron-deficient levels into the healthy range. Iron stores have improved significantly and remain stable.
  • ✓Serum iron and transferrin saturation have remained stable.
  • ✓The current pattern supports monitoring rather than automatic additional iron replacement.
Recommendation: Continue periodic monitoring as advised by your healthcare provider.

What Doctors Look For

IronIron available today in your blood
FerritinStored iron in your body
TIBCBlood’s capacity to carry iron
SaturationEfficiency of iron transport

Iron & Liver Health

In people with chronic liver disease, ferritin alone can sometimes be misleading because inflammation may artificially increase ferritin levels. For this reason, iron, ferritin, TIBC and transferrin saturation should always be interpreted together rather than individually.

Smart AI Insights

  • ✓Iron deficiency resolved
  • ✓Iron stores stable
  • ✓No evidence of iron overload
  • ✓Continue periodic monitoring
AI information is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.
⌂Medical Data›Ultrasound Reports›Liver›June 12, 2026
RS MEDICAL IMAGING

Ultrasound Reports

AUTOMATED LONGITUDINAL REVIEW

AI Imaging Summary

Updates with report data

A simple, data-driven explanation of how the ultrasound findings changed over time. This summary currently covers February 2023 through June 2026.

✓

Liver cancer surveillance

No suspicious liver mass was reported in any of the ultrasound studies currently entered.

↗

Portal vein history

A nonocclusive portal vein thrombus was reported in April 2025. The latest Doppler study reports patent portal veins, hepatopetal flow and no evidence of portal venous thrombosis on that examination.

≈

Liver and portal hypertension

Earlier imaging described a smooth or normal-appearing liver. Later studies describe nodular cirrhotic morphology and portal hypertension. Splenomegaly has been a persistent associated finding.

↓

Ascites trend

Feb 2023 None
Feb 2024 None
Aug 2024 None
Apr 2025 Moderate
Jun 2026 Trace

Ascites was not identified on the 2023 or 2024 ultrasound studies, increased to moderate in April 2025, and was described as trace on the June 2026 Doppler ultrasound. The newest report therefore documents less abdominal fluid than the 2025 study.

What this means in simple language

Your ultrasound history shows chronic liver disease that became more clearly cirrhotic over time. A portal vein clot was seen in 2025, while the newest Doppler ultrasound did not show that clot and confirmed blood was flowing toward the liver. Fluid in the abdomen increased to a moderate amount in 2025 and was only trace on the newest study. The reports consistently show no suspicious liver mass.

How automation works

This panel is generated from the structured findings inside the widget. Adding or changing a report automatically recalculates the date range, portal-vein history, ascites sequence, liver morphology and mass-surveillance statement.

Vascular Duplex

Ultrasound Vascular Duplex Scan

Abdomen vascular flow — complete

Source: Original radiology report
Exam dateJune 12, 2026
ComparisonCT abdomen 03/06/2026
Study qualityTechnically adequate
Report signed06/16/2026 3:40 PM
Interpreting physicianDianna Y. Howard, MD

Key Impression

1

No evidence of portal venous thrombosis.

2

Cirrhosis with portal hypertension.

3

Trace ascites.

Liver Findings

Liver morphologyNodular cirrhotic liver with prominent caudate lobe
Suspicious liver massNone identified
Main portal veinPatent
Portal flow directionHepatopetal (toward liver)
Portal velocity15.5 cm/s
Portal vein diameter1.0 cm
Right portal veinPatent with hepatopetal flow
Left portal veinPatent with hepatopetal flow
Portal venous thrombosisNo evidence
AscitesTrace

Abdominal Findings

GallbladderDiffuse wall thickening up to 7.7 mm, similar to prior CT and attributed to underlying liver disease
Common bile ductNormal diameter, up to 0.6 cm
SpleenSplenomegaly, 17.4 × 8.7 × 16.0 cm
Inferior vena cavaUnremarkable
Free fluidTrace ascites

Vascular Doppler Findings

VesselPatencyFlow / finding
Common hepatic arteryPatentUnremarkable
Splenic veinPatentHepatopetal flow
Main portal veinPatentHepatopetal flow
Right portal veinPatentHepatopetal flow
Left portal veinPatentHepatopetal flow
Right hepatic vein—Unremarkable
Middle hepatic vein—Unremarkable
Left hepatic vein—Unremarkable
Inferior vena cava—Unremarkable

Clinical Summary

This view organizes the report into structured findings so a clinician can scan the study quickly. Original wording remains available under Technical Report.

Technique and source wording

Grayscale, color Doppler and spectral waveform analysis of the right upper quadrant and liver vessels.

Impression: No evidence of portal venous thrombosis. Cirrhosis with portal hypertension. Trace ascites.

Plain-language explanation

This section translates medical terms without changing the original report. “Hepatopetal” means blood is flowing toward the liver. “Patent” means the vessel is open. Findings must be interpreted alongside the complete medical record by the treating clinician.

HCC Screening

Liver Ultrasound — HCC Screening

Hepatocellular carcinoma surveillance

Source: Original radiology report
Exam dateApril 28, 2025
ComparisonPrior ultrasound 02/25/2024; subsequent CT 05/02/2025
Study qualityReport complete
Report signed05/05/2025 6:02 AM
Interpreting physicianClark Brixey, MD

Key Impression

1

Diffuse hepatocellular disease with no mass.

2

Nonocclusive portal vein thrombus.

3

Moderate ascites.

Liver Findings

Liver length13.7 cm
EchotextureHeterogeneous
Liver contourNodular
Liver massNone
Main portal veinNonocclusive thrombus
Portal flow directionNormal directional flow
Portal vein diameter1.3 cm
AscitesModerate

Abdominal Findings

Four abdominal quadrantsModerate ascites

Vascular Doppler Findings

VesselPatencyFlow / finding
Main portal veinPartially patentNonocclusive thrombus with maintained directional flow

Clinical Summary

This view organizes the report into structured findings so a clinician can scan the study quickly. Original wording remains available under Technical Report.

Technique and source wording

Multiple transverse and longitudinal grayscale images with color Doppler and spectral analysis as needed.

Impression: Diffuse hepatocellular disease with no mass. Nonocclusive portal vein thrombus. Moderate ascites.

Plain-language explanation

This section translates medical terms without changing the original report. “Hepatopetal” means blood is flowing toward the liver. “Patent” means the vessel is open. Findings must be interpreted alongside the complete medical record by the treating clinician.

RUQ / Limited Abdomen

Limited Abdominal Ultrasound

Right upper quadrant and spleen

Source: Original radiology report
Exam dateAugust 25, 2024
ComparisonRUQ ultrasound 02/25/2024
Study qualityReport complete
Report signed08/26/2024 7:12 AM
Interpreting physicianZsoka E. Vajtai, MD

Key Impression

1

Diffuse increased hepatic echogenicity consistent with chronic hepatocellular disease.

2

Splenomegaly.

3

4 mm circumferential gallbladder wall thickening.

Liver Findings

Right hepatic lobe16.1 cm
EchogenicityDiffusely increased
Liver contourSmooth
Liver massNone
Main portal veinPatent
Portal flowNormal hepatopetal
Portal vein diameter1.3 cm
AscitesNone

Abdominal Findings

PancreasVisualized portion unremarkable
GallbladderUnderdistended with 4 mm circumferential wall thickening
GallstonesNone
Pericholecystic fluidNone
Spleen19 × 17 × 9 cm (1520 mL)
Free fluidNone

Vascular Doppler Findings

VesselPatencyFlow / finding
Main portal veinPatentNormal hepatopetal flow

Clinical Summary

This view organizes the report into structured findings so a clinician can scan the study quickly. Original wording remains available under Technical Report.

Technique and source wording

Multiple transverse and longitudinal grayscale images of the RUQ and spleen with color Doppler and spectral analysis as needed.

Impression: Diffuse increased hepatic echogenicity consistent with chronic hepatocellular disease. Splenomegaly. 4 mm circumferential gallbladder wall thickening.

Plain-language explanation

This section translates medical terms without changing the original report. “Hepatopetal” means blood is flowing toward the liver. “Patent” means the vessel is open. Findings must be interpreted alongside the complete medical record by the treating clinician.

HCC Screening

Liver Ultrasound — HCC Screening

Hepatocellular carcinoma surveillance

Source: Original radiology report
Exam dateFebruary 25, 2024
Comparison02/19/2023
Study qualityReport complete
Report signed02/29/2024 8:12 AM
Interpreting physicianTeran Colen, MD

Key Impression

1

Diffuse hepatocellular disease.

2

No liver mass detected.

3

Splenomegaly.

Liver Findings

EchotextureHyperechoic
Liver massNone detected
Main portal veinPatent
Portal flowNormal directional flow
AscitesNone

Abdominal Findings

SpleenEnlarged, 19.7 cm
Focal splenic abnormalityNone

Vascular Doppler Findings

VesselPatencyFlow / finding
Main portal veinPatentNormal directional flow

Clinical Summary

This view organizes the report into structured findings so a clinician can scan the study quickly. Original wording remains available under Technical Report.

Technique and source wording

Multiple transverse and longitudinal grayscale liver images with color Doppler and spectral analysis as needed.

Impression: Diffuse hepatocellular disease. No liver mass detected. Splenomegaly.

Plain-language explanation

This section translates medical terms without changing the original report. “Hepatopetal” means blood is flowing toward the liver. “Patent” means the vessel is open. Findings must be interpreted alongside the complete medical record by the treating clinician.

RUQ / Limited Abdomen

Limited Right Upper Quadrant Ultrasound

Baseline RUQ study

Source: Original radiology report
Exam dateFebruary 19, 2023
ComparisonNone listed
Study qualityReport complete
Report signed02/19/2023 11:41 AM
Interpreting physicianZsoka E. Vajtai, MD

Key Impression

1

No sonographic right upper quadrant abnormality to correlate with symptoms.

2

Patent portal vein with normal hepatopetal flow.

3

No ascites.

Liver Findings

Right hepatic lobe17.9 cm
EchotextureWithin normal limits
Liver contourSmooth
Liver massNone
Main portal veinPatent
Portal flowNormal hepatopetal
Portal vein diameter1.3 cm
AscitesNone

Abdominal Findings

PancreasVisualized portion unremarkable
Common bile duct0.4 cm, normal
GallbladderNo wall thickening, gallstone or pericholecystic fluid
Sonographic Murphy signAbsent
Right kidney14.3 cm; no stone or hydronephrosis
Free fluidNone

Vascular Doppler Findings

VesselPatencyFlow / finding
Main portal veinPatentNormal hepatopetal flow

Clinical Summary

This view organizes the report into structured findings so a clinician can scan the study quickly. Original wording remains available under Technical Report.

Technique and source wording

Multiple transverse and longitudinal grayscale RUQ images with color Doppler and spectral analysis as needed.

Impression: No sonographic right upper quadrant abnormality to correlate with symptoms. Patent portal vein with normal hepatopetal flow. No ascites.

Plain-language explanation

This section translates medical terms without changing the original report. “Hepatopetal” means blood is flowing toward the liver. “Patent” means the vessel is open. Findings must be interpreted alongside the complete medical record by the treating clinician.

This structured summary is based on the original radiology reports and is for informational purposes only. It does not replace the original report or professional medical advice.
Curated by RS • Source: Original radiology reports • Updated August 2026

Ultrasound Report

Vascular Duplex Scan
June 12, 2026CT abdomen · March 6, 2026

Key Findings

Liver
Cirrhosis
Nodular morphology. No suspicious mass.
Portal Vein
Patent
Forward hepatopetal flow · 15.5 cm/s
Spleen
Enlarged
17.4 × 8.7 × 16.0 cm
Ascites
Trace
Very small amount of abdominal fluid

Organ Findings

Liver
Nodular cirrhotic liver with prominent caudate lobe. No suspicious mass.
Gallbladder
Diffuse wall thickening up to 7.7 mm, similar to prior CT and reflective of underlying liver disease.
Common Duct
Normal common duct diameter measuring up to 0.6 cm.
Spleen
Splenomegaly measuring 17.4 × 8.7 × 16.0 cm.
Inferior Vena Cava
Unremarkable.

Trace Ascites

What this means
A trace amount of free fluid was seen in the abdomen. “Trace” is the smallest amount commonly described on imaging and often causes no symptoms.
Why it can happen
Cirrhosis can increase pressure in the portal circulation. Along with changes in how the body handles sodium and water, this can allow fluid to collect in the abdominal cavity.
Your current finding
Only trace fluid was reported—not moderate or large-volume ascites. It usually does not require drainage, but it should continue to be monitored.
Contact your healthcare team if you notice
  • Rapid increase in abdominal size
  • Sudden weight gain over several days
  • Fever or significant abdominal pain
  • Shortness of breath
  • New confusion

Report Interpretation

This ultrasound shows chronic cirrhosis with portal hypertension, but no portal venous thrombosis. Portal blood flow remains open and travels in the expected direction. Trace ascites is present, representing a very small amount of abdominal fluid. No suspicious liver mass was reported.
This is a personal health-tracking summary of the radiology report and is not a substitute for professional medical interpretation.
RS MEDICAL IMAGING

CT Scan & Portal Vein Imaging Timeline

A chronological view of liver morphology, portal vein thrombosis, portal hypertension, spleen size, ascites, and liver-mass surveillance.

Baseline Doppler Ultrasound Feb 20, 2023
AI

AI Imaging Summary

Portal veins patent; no imaging evidence of cirrhosis

The liver appeared homogeneous without a mass. The main, right, and left portal veins were patent with normal forward flow. No ascites was present. The major abnormality was marked splenomegaly measuring 20.1 cm.

Portal Vein Patent with normal hepatopetal flow
Liver Homogeneous; no mass; no cirrhosis reported
Spleen 20.1 cm — enlarged
Ascites None
Liver Mass None

What changed from the previous study?

Establishes the earliest vascular baseline before later CT-documented thrombosis.

Portal Vein Thrombosis Tracker
This timeline summarizes the radiology reports provided. It does not replace the original report or professional medical interpretation.
LIVER HEALTH GROUP
My Data. My Journey. My Fight.

Comprehensive Health Analysis

Personalized AI Review of Your Medical Data

Last UpdatedAugust 28, 2026Next ReviewSeptember 28, 2026Auto Update  •  Monthly
MELD 3.0 SCORE
10
Calculated TodayLow Risk (<15)Stable over the last 5 tests
LIVER FUNCTION STATUS

Stable

Your liver function is stable with preserved synthetic capacity.

AI ConfidenceHighData QualityExcellent
MELD 3.0 TREND (Last 6 Tests)11Mar '2510May '2510Jul '2510Mar '2610May '2610Jul '26
Bilirubin 1.2 mg/dLINR 1.4 Creatinine 0.82 mg/dLSodium 139 mmol/LAlbumin 4.3 g/dLSex Male Recent Dialysis No

LIVER

Function & Reserve

Bilirubin1.2 mg/dL
Albumin4.3 g/dL
INR1.4
Creatinine0.82 mg/dL
Sodium139 mmol/L
Liver ReserveGOOD
80%

HEART

Circulation & Vital Signs

Blood Pressure110/68 mmHg
Resting HR52 bpm
Carvedilol EffectActive
Exercise ToleranceGood
Cardio StatusGOOD
80%

BLOOD

Hematology & Iron

Hemoglobin13.5 g/dL
Platelets72 K/µL
WBC2.5 K/µL
Ferritin123 ng/mL
Iron Saturation25%
Blood StatusIMPROVING
70%

METABOLIC

Metabolism & Nutrition

HbA1c5.8%
Total Cholesterol108 mg/dL
LDL46 mg/dL
HDL49 mg/dL
Triglycerides52 mg/dL
Metabolic StatusEXCELLENT
90%

MEDICATIONS

Current Regimen

Eliquis 5 mgTwice Daily
Carvedilol 6.25 mgTwice Daily
Atorvastatin 10 mgOnce Daily
AdherenceEXCELLENT
100%

AI CLINICAL FINDINGS

Evidence-based insights from your medical data

WHAT'S IMPROVED

  • Ferritin is now in normal range
  • Iron saturation optimized
  • Cholesterol levels are excellent
  • Diabetes is well controlled
  • Exercise consistency is excellent
  • MELD 3.0 score is stable at 10

NEEDS MONITORING

  • Platelet count remains low (72 K/µL)
  • WBC remains low (2.5 K/µL)
  • Portal hypertension
  • Esophageal varices surveillance
  • Portal vein thrombosis history
  • Sleep duration and quality

OVERALL ASSESSMENT

Your liver synthetic function remains preserved with a stable MELD 3.0 score of 10.

Portal hypertension remains the primary long-term concern and requires ongoing monitoring.

Cardiovascular, metabolic, and iron status are excellent with strong lifestyle consistency.

Overall status is stable.

ADDITIONAL INFORMATION

Laboratory TrendsHistorical blood-test results and changes over time.

Current Liver & MELD Inputs

  • Bilirubin: 1.2 mg/dL
  • INR: 1.4
  • Creatinine: 0.82 mg/dL
  • Sodium: 139 mmol/L
  • Albumin: 4.3 g/dL

Current Blood Results

  • Hemoglobin: 13.5 g/dL
  • Platelets: 72 K/µL
  • WBC: 2.5 K/µL
  • Ferritin: 123 ng/mL
  • Iron Saturation: 25%

MELD Trend

Current score: 10

11 → 10 → 10 → 10 → 10 → 10

The current point is generated from the same master laboratory values used by the Liver card.

Imaging and ProceduresUltrasound, CT, endoscopy, and treatment history.

Latest Vascular Ultrasound

Stable vascular findings. The main, right, and left portal veins were patent with forward hepatopetal flow. No portal venous thrombosis was detected.

Key Imaging Findings

  • Nodular cirrhotic liver; no suspicious mass reported.
  • Portal-vein flow measured 15.5 cm/s.
  • Splenomegaly measured 17.4 × 8.7 × 16.0 cm.
  • Trace ascites was present.

Monitoring Context

The report continues to support cirrhosis with portal hypertension, while the portal venous system remains open. Imaging and endoscopy surveillance should follow the treating team’s schedule.

Medication and Activity ContextCurrent medications, exercise, heart rate, sleep, and steps.

Current Medications

  • Eliquis 5 mg: Twice Daily
  • Carvedilol 6.25 mg: Twice Daily
  • Atorvastatin 10 mg: Once Daily

Eliquis and carvedilol are taken twice daily together. Atorvastatin is taken once daily.

Heart & Medication Context

  • Blood Pressure: 110/68 mmHg
  • Resting HR: 52 bpm
  • Carvedilol Effect: Active
  • Exercise Tolerance: Good

Carvedilol can lower resting heart rate and blood pressure, so those readings are interpreted with medication context.

Activity Context

  • Average steps per day: 20,412
  • Cycling per week: 210 min
  • Active minutes per week: 480 min
  • Average sleep per night: 6h 45m
  • Gym frequency: 4–5 days/week

Activity values follow the same report data used by this widget and can be updated from Elementor or a connected health-data source.

LiverHealthGroup.comMy Data. My Journey. My Fight.
S.R

This AI analysis is based on the data you have provided and is for informational purposes only. It is not a substitute for professional medical advice.

Translate to Any Language

Use our translation widget to view all of our health information and resources in your preferred language instantly.

Translate Our Website to Any Language

Our built-in translator makes it easy to read all of our content and updates in any language, instantly.

  • ⚡Instant & Automatic
  • 🌐12 Languages
  • 🛡️SEO Friendly